Market News & Trends
ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity & Licenses GlymaxX
ProBioGen and ValenzaBio recently announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology. ValenzaBio's VB119 is a…
LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation
LEXEO Therapeutics recently announced that the US FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX1004 for the treatment of CLN2…
Catalent Launches New OptiDose Design Solution to Help Create Differentiated Treatments That Are Successful for Innovators, Patients & Health Care Professionals
Catalent recently announced the launch of its new OptiDose Design Solution, at the Controlled Release Society (CRS) annual meeting, which is took place virtually from July…
AMRI Becomes Curia
Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is…
Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and…
Strathclyde University conclude that membrane technology could revolutionize vaccine and therapeutics production
Whilst paying tribute to to the hugely impressive efforts of those who reconfigured existing equipment at speed into a "Generation 1" manufacturing process for mRNA…
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication Catalent, the leading global provider of advanced delivery…
Curia, the former AMRI, to Acquire Integrity Bio, Expanding Its Biologic Formulation and Fill-Finish Capabilities
One day after announcing its name change to Curia, leading contract research, development and manufacturing organization AMRI reported it has entered into a definitive agreement…
SPI Pharma launches UltraBurst™, the first in class preformulated platform for flash orally dispersible tablets.
SPI Pharma introduces UltraBurst™, providing a step-change in the most critical orally disintegrating tablet (ODT) characteristics — dissolution time. It is an innovative excipient platform…
Collaboration Between AbbVie, Biogen & Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health & Disease
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence…
Cyclerion Therapeutics & Beacon Biosignals Announce Expanded Strategic Partnership
Cyclerion Therapeutics, Inc. and Beacon Biosignals recently announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant…
Roquette Earns USDA Certified Biobased Product Label for BIOSUCCINIUM
Roquette recently announced it has earned the US Department of Agriculture (USDA) Certified Biobased Product label. The product, BIOSUCCINIUM® succinic acid, is now able to…
Nemera & BIOMM Sign Partnership Agreement to Commercialize Reusable Insulin Pen in Brazil
A pioneer in biotechnological medicines in Brazil, BIOMM is launching Nemera’s Advapen under the trade name Lifepen® for the administration of….
Evaxion Biotech Reports Data From Phase 1/2a Trials of EVX-01 & EVX-02
Evaxion Biotech A/S recently announced results from both its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of…
Ensysce Biosciences Receives Notice of Award for Year 3 of Multi-Year NIDA Grant for the Clinical Development of its Next-Generation Opioid Products With Overdose Protection
Ensysce Biosciences, Inc. recently announced receipt of the third year award of a multi-year grant from the National Institute on Drug Abuse (NIDA). This award…
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US FDA. Breakthrough Therapy Designation…
Akston Biosciences Announces Positive Phase 1 Data for Second-Generation COVID-19 Vaccine Candidate
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, recently announced positive results from a 60-subject, open-label, Phase 1 trial of AKS-452, its…
LGM Pharma Launches New Stand-Alone Analytical Services Offering for Drug Developers & Manufacturers
LGM Pharma, a long-time leader in API sourcing, completed a transformational acquisition last year of long-established CDMO NexGen Pharma. Among the many new capabilities LGM…
Recipharm Signs Memorandum of Understanding (MOU) for the Fill Finish of Vaccines & Biotherapeutics in Morocco
Global contract development and manufacturing organization (CDMO) Recipharm has recently signed an MOU, along with His Majesty the King of Morocco, Mohammed VI, the Moroccan Government and….
Brickell Biotech Announces Final Patient Completed in First US Phase 3 Pivotal Clinical Study & Patient Enrollment Completed in Second US Phase 3 Pivotal Clinical Study
Brickell Biotech, Inc. recently announced the final patient has completed the Phase 3 pivotal Cardigan I study, and that all planned patients have been enrolled in the Phase 3 pivotal Cardigan II study…..
